Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Baxter
Fuji
Julphar
QuintilesIMS
Chinese Patent Office
Johnson and Johnson
Mallinckrodt
Harvard Business School

Generated: May 28, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,513,249

« Back to Dashboard

Which drugs does patent 8,513,249 protect, and when does it expire?

Patent 8,513,249 protects MIRVASO and is included in one NDA.

This patent has sixty-four patent family members in twenty-four countries.
Summary for Patent: 8,513,249
Title:Methods and compositions for safe and effective treatment of erythema
Abstract: Improved methods and compositions for safe and effective treatment of erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical composition comprising about 0.4% to about 0.6% by weight of brimonidine and a pharmaceutically acceptable carrier.
Inventor(s): Graeber; Michael (Lawrenceville, NJ), Loesche; Christian (Valbonne, FR), Freidenreich; Philip (Yardley, PA), Liu; Yin-Sang (Princeton, NJ), Leoni; Matthew J. (Hampton, NJ)
Assignee: Galderma Laboratories, L.P. (Fort Worth, TX)
Application Number:13/456,976
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,513,249
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Drugs Protected by US Patent 8,513,249

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Galderma Labs Lp MIRVASO brimonidine tartrate GEL;TOPICAL 204708-001 Aug 23, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up Y TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,513,249

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,861,631 Methods and compositions for safe and effective treatment of erythema ➤ Sign Up
8,231,885 Compounds, formulations, and methods for ameliorating telangiectasis ➤ Sign Up
7,439,241 Compounds, formulations, and methods for treating or preventing rosacea ➤ Sign Up
8,993,571 Compounds, formulations, and methods for treating or preventing inflammatory skin disorders ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
McKesson
Teva
Covington
Merck
Johnson and Johnson
Boehringer Ingelheim
Moodys
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.